Articles
Efficacy outcomes in acute myeloid leukemia (AML) are poorer with advanced age and the presence of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
Building Bridges to Conquer Cancer, the theme of the 2013 annual American Society of Clinical Oncology (ASCO) meeting held in Chicago, IL, is an appropriate goal of all healthcare practitioners who specialize in hematology/oncology, including postgraduate year 2 (PGY-2) oncology pharmacy residents.
Building Bridges to Conquer Cancer, the theme of the 2013 annual American Society of Clinical Oncology (ASCO) meeting held in Chicago, IL, is an appropriate goal of all healthcare practitioners who specialize in hematology/oncology, including postgraduate year 2 (PGY-2) oncology pharmacy residents.
Efficacy outcomes in acute myeloid leukemia (AML) are poorer with advanced age and the presence of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
We all go to our local pharmacy to get prescriptions filled for ourselves or a loved one. We usually notice, primarily based on the copayment, whether the prescription drug we are getting is a trade name we may see in a television commercial or it is a generic drug.
Cindy is a 52-year-old female with non-Hodgkin lymphoma. She plans to undergo an autologous hematopoietic stem cell transplant (HSCT). When discussing the risks associated with HSCT, the oncologist warns Cindy that her white blood cells (WBCs) will become critically low as a result of high-dose chemotherapy.
CJ is a 62-year-old female beginning chemotherapy with doxorubicin and cyclophosphamide for stage III breast cancer. To minimize the risk of neutropenia-associated complications, it is planned for CJ to return to the clinic daily following chemotherapy for injections of a colony-stimulating factor (CSF) until her absolute neutrophil count exceeds 10,000 × 106/L.
In April 2011, the National Comprehensive Cancer Network (NCCN) convened a summit of key stakeholders regarding the issues surrounding biosimilars in oncology care. The working group subsequently published a sentinel white paper outlining the regulatory, scientific, and patient safety issues surrounding the development and expansion of biosimilars in oncology care.
Barnes-Jewish Hospital in St. Louis, Missouri, is affiliated with the Siteman Cancer Center and Washington University School of Medicine.
With the growing number of cancer survivors in the United States and around the world, supportive care has become of even greater importance for these patients.